Kailera Therapeutics, Inc.(KLRA)
$11.02-0.56 (-4.84%)
KLRA
Kailera Therapeutics, Inc. financials statements
$11.02
At close:-0.56 (-4.84%)
Kailera Therapeutics, Inc. (KLRA) Ratios
61 Followers
Kailera Therapeutics, Inc. Ratios
KLRA's free cash flow for Q3 2026 was $-133.67M. For the 2026 fiscal year, KLRA's free cash flow was increased by $0.00 and operating cash flow was $-133.67M. See a summary of the company’s cash flow.
| Ratios | Dec 25 |
|---|---|
| Liquidity Ratios | |
| Current Ratio | 12.01 |
| Quick Ratio | 12.01 |
| Cash Ratio | 3.45 |
| Solvency Ratio | -0.14 |
| Operating Cash Flow Ratio | -2.59 |
| Short-Term Operating Cash Flow Coverage | 0.00 |
| Net Current Asset Value | $ -491.21M |
| Leverage Ratios | |
| Debt-to-Assets Ratio | 0.02 |
| Debt-to-Equity Ratio | -0.03 |
| Debt-to-Capital Ratio | -0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 |
| Financial Leverage Ratio | -1.94 |
| Debt Service Coverage Ratio | 0.00 |
| Interest Coverage Ratio | 0.00 |
| Debt to Market Cap | 0.00 |
| Interest Debt Per Share | 0.09 |
| Net Debt to EBITDA | 0.95 |
| Profitability Margins | |
| Gross Profit Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Profit Margin | 0.00% |
| Pretax Profit Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Continuous Operations Profit Margin | 0.00% |
| Net Income Per EBT | 100.00% |
| EBT Per EBIT | 94.07% |
| Return on Assets (ROA) | -21.52% |
| Return on Equity (ROE) | 41.79% |
| Return on Capital Employed (ROCE) | -24.52% |
| Return on Invested Capital (ROIC) | -24.48% |
| Return on Tangible Assets | -21.52% |
| Earnings Yield | -4.86% |
| Efficiency Ratios | |
| Receivables Turnover | 0.00 |
| Payables Turnover | 0.00 |
| Inventory Turnover | 0.00 |
| Fixed Asset Turnover | 0.00 |
| Asset Turnover | 0.00 |
| Working Capital Turnover Ratio | 0.00 |
| Cash Conversion Cycle | 0.00 |
| Days of Sales Outstanding | 0.00 |
| Days of Inventory Outstanding | 0.00 |
| Days of Payables Outstanding | 0.00 |
| Operating Cycle | 0.00 |
| Cash Flow Ratios | |
| Operating Cash Flow Per Share | -1.02 |
| Free Cash Flow Per Share | -1.04 |
| Dividend Paid and CapEx Coverage Ratio | -57.57 |
| Capital Expenditure Coverage Ratio | -57.57 |
| Operating Cash Flow Coverage Ratio | -11.18 |
| Operating Cash Flow to Sales Ratio | 0.00 |
| Free Cash Flow Yield | -3.99% |
| Valuation Ratios | |
| Price-to-Earnings (P/E) Ratio | -20.63 |
| Price-to-Sales (P/S) Ratio | 0.00 |
| Price-to-Book (P/B) Ratio | -8.60 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -25.08 |
| Price-to-Operating Cash Flow Ratio | -25.51 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 |
| Enterprise Value Multiple | -18.46 |
| Enterprise Value | 2.92B |
| EV to EBITDA | -18.46 |
| EV to Sales | 0.00 |
| EV to Free Cash Flow | -23.85 |
| EV to Operating Cash Flow | -24.27 |
| Tangible Book Value Per Share | -3.02 |
| Shareholders’ Equity Per Share | -3.02 |
| Tax and Other Ratios | |
| Effective Tax Rate | 0.00 |
| Revenue Per Share | 0.00 |
| Net Income Per Share | -1.26 |
| Tax Burden | 1.00 |
| Interest Burden | 0.94 |
| Research & Development to Revenue | 0.00 |
| SG&A to Revenue | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 |
| Income Quality | 0.81 |
Currency in USD
